CAR-T Cell Therapy Resource Center
News & Information for Healthcare Professionals
CAR T-Cell Therapy HCP Guide – Solid Tumors
Solid Tumor Research: Ongoing
CAR T-cell therapy has shown great success in hematologic malignancies, such as non-Hodgkin's lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular...
CAR T-Cell Therapy HCP Guide – Efficacy and Safety of Zuma Trials
ZUMA-3 and ZUMA-4 Trials
In addition to the October 2017 approval for Non-Hodgkin lymphoma, Yescarta (axicabtagene ciloleucel) has shown impressive early results in difficult-to-treat patients...
CAR T-Cell Therapy HCP Guide – Use of Yescarta in Acute Lymphoblastic Leukemia
Use of Yescarta in Acute Lymphoblastic Leukemia
Yescarta (axicabtagene ciloleucel) is also under late Phase 1 research for treatment of refractory or relapsed acute...
Cancer recurrence may be stopped with immunotherapy
October 17, 2017 (Medical News Today)
Scientists and researchers from the UK have set out to investigate why cancer often returns in patients whose...
CAR T-Cell Therapy HCP Guide – Is There A Universal CAR-T Cell Therapy?
Creating a universal CAR T agent could help avoid the lengthy and sometimes dangerous time period from apheresis of T-cells to re-infusion, which on...
CAR T-Cell Therapy HCP Guide – What Studies Are Ongoing With CAR T-Cell Therapy?
While side effects can be challenging, the fact remains that complete and partial remissions are impressive with CAR T-cell therapy. All eligible patients have...
CAR T-Cell Therapy HCP Guide – Is CAR T-Cell Therapy Approved?
At a July 2017 FDA Oncology Advisory Committee meeting, the panel reviewed Novartis’ CTL019 (tisagenlecleucel), an agent for aggressive pediatric and young adult acute...
CAR T-Cell Therapy HCP Guide – Updates from the FDA
CAR T-Cell FDA Approval: Status Update
In addition to the approval of Kymriah, Yescarta (axicabtagene ciloleucel or Axi-Cel) was approved on October 18,...
VIDEO: CAR T-cell Therapy for Pediatric Leukemia: Sam’s Story
Published September 18, 2017
CAR T-cell therapy is a revolutionary immunotherapy treatment that supercharges a patient's own blood cells to seek out and destroy...
Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy
September 6, 2017 (HealthDay News)
In leukemia/lymphoma, after treatment CD19-targeting chimeric antigen receptor T-cell therapy
Outcomes of treatment with third-generation CAR T-cell therapy in CD19-positive...
